Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02717611
Recruitment Status : Active, not recruiting
First Posted : March 24, 2016
Last Update Posted : September 19, 2019
Sponsor:
Information provided by (Responsible Party):
Acerta Pharma BV